Optimer inhibitors deliver the hot start control your high-fidelity enzymes need. Download the application note to learn how: Optimer inhibits both polymerase and exonuclease activity at ambient temperature and…
Choosing the right affinity ligand is the key to success in cell and tissue applications—especially for effective cell targeting and reliable biomarker discovery. Lack of reagent compatibility with cell…
Cell screens can be included in the aptamer discovery process, providing built-in validation for your binder. In most affinity ligand discovery processes, whether for…
Using multiple discovery methods in aptamer development provides better binders. Learn why multiple discovery methods are important, which is right for you and how they can be combined for…
Uncover disease-defining biomarkers by starting with cellular phenotypes, not predetermined targets. Why do we need new biomarkers? Traditional biomarker discovery relies on testing predetermined targets…
Cancer remains a mammoth challenge, accounting for one in every six deaths globally. But aptamers are offering new solutions from reagents to next-gen ADCs. Despite the scale of the…
In this webinar Aptamer’s Chief Scientific Officer, Dr David Bunka, discusses how Optimers can be used for developing cancer research reagents, new therapies and diagnostic tools. Aptamers, initially discovered…
Optimer® are novel reagents for use in IHC applications to localise new biomarkers and improve accuracy for current biomarkers, in both FFPE and frozen tissues. Download this application note to…
When selecting the right IHC reagent make sure you consider these three factors and find out how IHC aptamers can help ensure success from the start. Immunohistochemistry, IHC for short,…
Join experts, including Aptamer Group CTO, Dr David Bunka, for a conversation on recent progress in cancer research, including novel treatments, experimental therapies, and drug development.
